Compare United Airlines Holdings Inc (UAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Airlines Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? United Airlines Holdings Inc trades at $107.28 (market cap $34.87B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: United Airlines Holdings Inc is far larger — about 3.4× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United Airlines Holdings Inc for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UAL | XBI | |
|---|---|---|
Market Cap | $34.87B | $10.11B |
Volume | 6,329,678 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $136.11 | $169.55 |
52-Week Low | $85.21 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $51.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
United Airlines (UAL) trades at $107.46, down 2.46% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 10.1 and P/S of 0.6, supported by consistent earnings beats and improving profitability. Recent news highlights aggressive customer acquisition strategies targeting Delta's premium travelers through status-match offers and Starlink-enabled WiFi advantages.
UAL presents a compelling value opportunity with analyst consensus price target of $158.10 (47% upside) and unanimous buy/hold ratings. However, near-term headwinds include rising fuel costs, labor expenses, and technical weakness. The company's strong cash flow generation and strategic positioning for premium customer capture support long-term growth prospects despite current market pessimism.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
